NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TG Therapeutics, Inc. TGTX, GoodRx Holdings, Inc. GDRX, Agrify Corporation AGFY, and Pegasystems, Inc. PEGA. Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
TG Therapeutics, Inc. TGTX
On November 30, 2021, TG Therapeutics issued a press release "announc[ing] the U.S. Food and Drug Administration (FDA) has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA) for the combination of ublituximab and UKONIQ® (umbralisib) (combination referred to as U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)." TG Therapeutics advised that "[t]he FDA has notified the Company that potential questions and discussion topics for the ODAC include: the benefit-risk of the U2 combination in the treatment of CLL or SLL, and the benefit-risk of UKONIQ in relapsed/refractory marginal zone lymphoma (MZL) or follicular lymphoma (FL). In addition, as part of the benefit-risk analysis, the overall safety profile of the U2 regimen, including adverse events (serious and Grade 3-4), discontinuations due to adverse events, and dose modifications, is expected to be reviewed", stating that "[t]he FDA's concern giving rise to the ODAC meeting appears to stem from an early analysis of overall survival from the UNITY-CLL trial."
On this news, TG Therapeutics' stock price fell $8.16 per share, or 34.93%, to close at $15.20 per share on November 30, 2021.
For more information on the TG Therapeutics investigation go to: https://bespc.com/cases/TGTX
GoodRx Holdings, Inc. GDRX
On May 9, 2022, after the market closed, GoodRx announced its first quarter 2022 financial results and withdrew its fiscal 2022 guidance. In its shareholder letter, the Company stated that "a grocery chain had taken actions that impacted acceptance of discounts from most PBMs for a subset of drugs." The Company expects "the grocer issue . . . could have an estimated revenue impact of roughly $30 million [and] will be ongoing without amelioration through Q2." As a result, GoodRx "believe[s] it is unlikely [it] will be able to achieve the FY 2022 guidance" previously provided.
On this news, GoodRx's stock fell $2.78, or 25.9%, to close at $7.97 on May 10, 2022, thereby injuring investors.
For more information on the GoodRx investigation go to: https://bespc.com/cases/GDRX
Agrify Corporation AGFY
On December 16, 2021, during trading hours, market analyst Bonitas Research published a report regarding Agrify which alleges several issues at the Company including that "[w]e believe that Agrify created artificial demand for its product by financing undisclosed Company insiders to act as independent customers." Further the report alleges that "Agrify insiders lied to investors about the independence of its customer base in order to execute a dubious stock promotion for self-enrichment at the expense of minority shareholders[,]" and that "[e]vidence showed that five (5) of Agrify's eight (8) customer announcements in 2021 are either with undisclosed Company insiders or with unlicensed unproven operators."
On this news, Agrify's common stock price fell sharply during intraday trading on December 16, 2021.
For more information on the Agrify investigation go to: https://bespc.com/cases/AGFY
Pegasystems, Inc. PEGA
On May 10, 2022, Appian announced that it has received a verdict from a jury in the Circuit Court for Fairfax County, Virginia, awarding it $2.036 billion in damages from Pegasystems Inc. PEGA for trade secret misappropriation. The jury also found that Pegasystems violated the Virginia Computer Crimes Act. The jury further found Pegasystems' misappropriation of Appian's trade secrets to be willful and malicious. Appian brought the case to trial to ensure the protection of its proprietary intellectual property, including its trade secrets.
On this news, Pegasystems' stock dropped $13.68, or 20.75%, to close at $52.25.
For more information on the Pegasystems investigation go to: https://bespc.com/cases/PEGA
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
